PRECIOUS the group
PRECIOUS the group
PRECIOUS the group

Partner 14 - CTC North

Dr. Saskia Borregaard



Dr. Saskia Borregaard


Project Leader


Phone: +49 40 524719200

Fax: +49 40 524719119 



CTC North GmbH & Co. KG


Martinistraße 64

20251 Hamburg





Dr. Iris Alpers

Dr. Iris Alpers


Safety Manager

Phone: +49 40 524719213

Fax: +49 40 524719129






Institute presentation

The undefinedClinical Trial Center North (CTC North) is an independent full service CRO located on the campus of the undefinedUniversity Medical Center Hamburg-Eppendorf (UKE). Its objective is to guarantee the professional conduct of clinical trials in accordance with ICH-GCP, the German Drug Law (AMG) and the German Medical Device Law (MPG) within a university environment. CTC North provides professional services in all aspects of clinical trials and offers complete clinical trial management complying with regulatory guidelines valid worldwide and the highest quality assurance standards. CTC North acts as an advisor to investigators and scientists and provides a variety of support services related to conducting clinical trials. CTC North has extensive experience with the coordination of multicenter clinical trials, with a focus on studies with non-commercial sponsors (IITs). The following services are provided: Project management, regulatory services, medical writing, safety monitoring, monitoring, data management, and statistics.


With the PRECIOUS study CTC North and UKE continue their successful history of collaboration in clinical stroke research with coordination of European stroke trials.


Main tasks attributed in the project:


CTC North will contribute to undefinedWP6 (Safety monitoring) together with the undefinedUKE (participant 12). The overall aim of the PRECIOUS trial is to improve the treatment of patients with acute ischaemic stroke or intracerebral haemorrhage. Thus, the safety of patients is of highest priority throughout the enrolment in the clinical trial. The main responsibility of WP 6 is to assure the safety of the patients enrolled in the clinical trial by:


  • Documentation and evaluation of all reported SAEs
  • MedDRA Coding of SAEs
  • Reporting of SAEs and SUSARs to the relevant authorities
  • Development of Annual Safety Reports (DSUR)
  • Development of Final Safety Report
  • Preparation of SAE / SUSAR Listings for the DSMB


and perform a continuous risk/benefit evaluation and consideration based on the above named actions.


CTC North will also contribute to undefinedWP1 (Trial Management) and will be responsible for national regulatory submission and trial coordination in Germany together with the undefinedUKE (participant 12).


Newsletter Subscription

Social Media


Contact us

Contact us